Dextromethorphan-Bupropion Combination for Extended Plasma Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neurological and psychiatric conditions, particularly those involving dextromethorphan, face challenges such as rapid metabolism leading to short plasma half-life and adverse events, necessitating frequent dosing and loss of efficacy.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels, and reduce adverse events by extending the metabolic lifetime and decreasing dextrorphan plasma levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If dextromethorphan is administered alone, then the treatment is simple, but the plasma half-life is short due to rapid metabolism requiring frequent dosing
Solution Approach 1:
Bupropion is introduced as an intermediary substance that inhibits the metabolism of dextromethorphan. This mediator extends the plasma half-life of dextromethorphan by blocking its metabolic breakdown, thereby reducing the frequency of dosing required while maintaining therapeutic effectiveness.
Solution Approach 2:
The pharmacokinetic parameters of dextromethorphan are changed by co-administration with bupropion. Specifically, the plasma half-life is extended and the concentration-time profile is modified, allowing for less frequent dosing while maintaining adequate therapeutic levels.
2Reliability
If dextromethorphan is administered at high doses to maintain efficacy, then the therapeutic effect is improved, but adverse events increase
Solution Approach 1:
Bupropion acts as a protective intermediary that prevents the formation of toxic metabolites from dextromethorphan. By inhibiting metabolic pathways that produce harmful substances, bupropion allows for effective dextromethorphan dosing while reducing adverse events associated with high doses.
Solution Approach 2:
The metabolic interaction between bupropion and dextromethorphan converts potentially harmful rapid metabolism into a beneficial extended half-life effect. This transformation allows therapeutic doses to be maintained without the adverse effects typically associated with high-dose administration.
3Reliability
If dextromethorphan is dosed frequently to maintain plasma levels, then the therapeutic effect is maintained, but the loss of efficacy over time increases
Solution Approach 1:
Bupropion serves as a temporal mediator that extends the duration of dextromethorphan's therapeutic action. By slowing metabolism, it increases the time between effective doses, reducing the frequency of administration while maintaining therapeutic reliability.
Solution Approach 2:
The temporal parameters of dextromethorphan's action are modified by bupropion co-administration. The extended plasma half-life directly increases the time between doses, allowing for less frequent administration while maintaining consistent therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances dextromethorphan plasma levels, reduces adverse events, and allows for less frequent dosing without loss of efficacy, thereby improving therapeutic outcomes for neurological disorders.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels, and reduce adverse events by extending the metabolic lifetime
Implementation Method 2
decreasing dextrorphan plasma levels
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.